310 related articles for article (PubMed ID: 35052876)
1. Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.
Moreno-Vedia J; Girona J; Ibarretxe D; Masana L; Rodríguez-Calvo R
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052876
[TBL] [Abstract][Full Text] [Related]
2. Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.
De Cól JP; de Lima EP; Pompeu FM; Cressoni Araújo A; de Alvares Goulart R; Bechara MD; Laurindo LF; Méndez-Sánchez N; Barbalho SM
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612504
[TBL] [Abstract][Full Text] [Related]
3. Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease.
Rodríguez-Calvo R; Girona J; Alegret JM; Bosquet A; Ibarretxe D; Masana L
J Endocrinol; 2017 Jun; 233(3):R173-R184. PubMed ID: 28420707
[TBL] [Abstract][Full Text] [Related]
4. Update on genetics and epigenetics in metabolic associated fatty liver disease.
Zhu X; Xia M; Gao X
Ther Adv Endocrinol Metab; 2022; 13():20420188221132138. PubMed ID: 36325500
[TBL] [Abstract][Full Text] [Related]
5. Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD).
Buzova D; Maugeri A; Liguori A; Napodano C; Lo Re O; Oben J; Alisi A; Gasbarrini A; Grieco A; Cerveny J; Miele L; Vinciguerra M
Clin Epigenetics; 2020 Aug; 12(1):126. PubMed ID: 32819448
[TBL] [Abstract][Full Text] [Related]
6. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease.
Gish R; Fan JG; Dossaji Z; Fichez J; Laeeq T; Chun M; Boursier J
Hepatol Int; 2024 Jun; ():. PubMed ID: 38850496
[TBL] [Abstract][Full Text] [Related]
7. Adipose-Derived Fatty Acid-Binding Proteins Plasma Concentrations Are Increased in Breast Cancer Patients.
Guaita-Esteruelas S; Saavedra-García P; Bosquet A; Borràs J; Girona J; Amiliano K; Rodríguez-Balada M; Heras M; Masana L; Gumà J
Oncologist; 2017 Nov; 22(11):1309-1315. PubMed ID: 28701570
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
Sotoudeheian M
Protein Pept Lett; 2024 May; ():. PubMed ID: 38715329
[TBL] [Abstract][Full Text] [Related]
9. Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease.
Zhang N; Tian X; Yan T; Wang H; Zhang D; Lin C; Liu Q; Jiang S
Front Immunol; 2023; 14():1148722. PubMed ID: 37020540
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.
Mărginean CO; Meliț LE; Săsăran MO
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944682
[TBL] [Abstract][Full Text] [Related]
12. The metabolic profiles and body composition of lean metabolic associated fatty liver disease.
Cheng YM; Kao JH; Wang CC
Hepatol Int; 2021 Apr; 15(2):405-412. PubMed ID: 33539004
[TBL] [Abstract][Full Text] [Related]
13. Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk.
Rodríguez-Calvo R; Moreno-Vedia J; Girona J; Ibarretxe D; Martínez-Micaelo N; Merino J; Plana N; Masana L
Front Physiol; 2021; 12():781789. PubMed ID: 34966292
[No Abstract] [Full Text] [Related]
14. Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype.
Mazzini FN; Cook F; Gounarides J; Marciano S; Haddad L; Tamaroff AJ; Casciato P; Narvaez A; Mascardi MF; Anders M; Orozco F; Quiróz N; Risk M; Gutt S; Gadano A; Méndez García C; Marro ML; Penas-Steinhardt A; Trinks J
Metabolomics; 2021 Jun; 17(7):58. PubMed ID: 34137937
[TBL] [Abstract][Full Text] [Related]
15. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease.
Huang J; Ou W; Wang M; Singh M; Liu Y; Liu S; Wu Y; Zhu Y; Kumar R; Lin S
Risk Manag Healthc Policy; 2021; 14():491-501. PubMed ID: 33603515
[TBL] [Abstract][Full Text] [Related]
16. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
[TBL] [Abstract][Full Text] [Related]
17. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis.
Ke Y; Liu S; Zhang Z; Hu J
Lipids Health Dis; 2021 May; 20(1):55. PubMed ID: 34034750
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
[TBL] [Abstract][Full Text] [Related]
19. Metabolic-associated fatty liver disease and sarcopenia: A double whammy.
Viswanath A; Fouda S; Fernandez CJ; Pappachan JM
World J Hepatol; 2024 Feb; 16(2):152-163. PubMed ID: 38495287
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem.
Le Garf S; Nègre V; Anty R; Gual P
Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
